AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23552179 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate infusion
Number of subjects: 195
Study 23552179 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (in subset with baseline creatinine clearance < 60 mL/min)
Number of subjects: 195
Study 23552179 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate infusion (in subset with baseline creatinine clearance < 60 mL/min)
Number of subjects: 195
Study 22037701 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode surface area 254 mm(2) with 30 s sampling time
Number of subjects: 120
Study 22037701 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode surface area 474 mm(2) with 30 s sampling time
Number of subjects: 120
Study 22037701 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode surface area 254 mm(2) with 7.5 s sampling time
Number of subjects: 120
Study 22037701 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode surface area 474 mm(2) with 7.5 s sampling time
Number of subjects: 120
Study 17265545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (18 weeks, 45 min, twice a week)
Number of subjects: 49
Study 17265545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study 16100235 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (glucose-insulin-potassium) treatment
Number of subjects: 21
Study 16100235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 16100235 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK treatment
Number of subjects: 21
Study 16100235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 11900099 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants cued to forget the 1st of 2 studied lists before studying the 2nd
Number of subjects: 0
Study 11900099 — intervention group
Group type: COMPARATOR
Intervention: Providing some studied words as cues during recall
Number of subjects: 0
Study 10521999 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus ampicillin/salbactum (1.5 gm i.v. loading then 750 mg q 9 am, 3 pm, & 9 pm)
Number of subjects: 138
Study 10521999 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus metronidazole and erythromycin (both 500 mg i.v. q 9 am, 3 pm, & 9 pm)
Number of subjects: 138
Study 10521999 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus erythromycin (both 500 mg i.v. q 9 am, 3 pm, & 9 pm)
Number of subjects: 138
Study 10521999 — intervention group
Group type: COMPARATOR
Intervention: Oral dual therapy (omeprazole 20 mg and amoxycillin 1 g bid x 2 weeks)
Number of subjects: 138
Study 10521999 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day intravenous regimens (Groups 1-3)
Number of subjects: 138
Study 7491890 — intervention group
Group type: EXPERIMENTAL
Intervention: 130 g dry lentils/d
Number of subjects: 9
Study 7491890 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 9
Study 1791775 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dydrogesterone
Number of subjects: 30
Study 1791775 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dydrogesterone
Number of subjects: 30
Study 1791775 — intervention group
Group type: COMPARATOR
Intervention: Control (50 mg oestradiol implant)
Number of subjects: 30
Study 6754212 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonantradol 0.5 mg
Number of subjects: 0
Study 6754212 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonantradol 0.75 mg
Number of subjects: 0
Study 6754212 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine 26 mg
Number of subjects: 0
Study 31550775 — intervention group
Group type: EXPERIMENTAL
Intervention: HGSC-SET I (25%-50%)
Number of subjects: 408
Study 31550775 — intervention group
Group type: EXPERIMENTAL
Intervention: HGSC-SET II (>50%)
Number of subjects: 408
Study 31550775 — intervention group
Group type: COMPARATOR
Intervention: HGSC-classic group (<25%)
Number of subjects: 408
Study 31550775 — intervention group
Group type: EXPERIMENTAL
Intervention: HGSC-SET I
Number of subjects: 408
Study 31550775 — intervention group
Group type: EXPERIMENTAL
Intervention: HGSC-SET II
Number of subjects: 408
Study 29975689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfers for school attendance
Number of subjects: 2533
Study 29975689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cash transfers)
Number of subjects: 2533
Study 25075979 — intervention group
Group type: EXPERIMENTAL
Intervention: BIG device
Number of subjects: 52
Study 25075979 — intervention group
Group type: COMPARATOR
Intervention: EZ-IO device
Number of subjects: 52
Study 25074283 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI-10 min × 20 °C
Number of subjects: 8
Study 25074283 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI-30 min × 20 °C
Number of subjects: 8
Study 25074283 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI-10 min × 10 °C
Number of subjects: 8
Study 25074283 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI-30 min × 10 °C
Number of subjects: 8
Study 25074283 — intervention group
Group type: COMPARATOR
Intervention: Passive rest (Control)
Number of subjects: 8
Study 22995043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 485)
Number of subjects: 700
Study 22995043 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 215)
Number of subjects: 700
Study 19732445 — intervention group
Group type: COMPARATOR
Intervention: Placebo group receiving 500 mg medicinal starch daily
Number of subjects: 140
Study 19732445 — intervention group
Group type: EXPERIMENTAL
Intervention: GTP group receiving 500 mg of GTP per day
Number of subjects: 140
Study 19732445 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo+TC group receiving both placebo treatment and TC training (60‐minute group exercise, 3 times per week)
Number of subjects: 140
Study 19732445 — intervention group
Group type: EXPERIMENTAL
Intervention: GTP+TC group receiving both GTP and TC training for 24 weeks
Number of subjects: 140
Study 17647187 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention based on the Health Belief Model (HBM) - two sessions of one hour each
Number of subjects: 206
Study 17647187 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic health education curriculum on osteoporosis
Number of subjects: 206
Study 17647187 — intervention group
Group type: COMPARATOR
Intervention: No specific educational program for osteoporosis prevention
Number of subjects: 206
Study 15607599 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate systemic hypothermia (33 degrees C) for 48 hours
Number of subjects: 65
Study 15607599 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37 degrees C) for 48 hours
Number of subjects: 65
Study 11856113 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular neourethral dilatation for 12 weeks (Group 1)
Number of subjects: 64
Study 11856113 — intervention group
Group type: COMPARATOR
Intervention: No neourethral dilatation (Group 2)
Number of subjects: 64
Study 10667742 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 183
Study 10667742 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 183
Study 10667742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of risperidone or haloperidol (maximum, < or = 6 mg/day)
Number of subjects: 183
Study 7790470 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterotoxigenic E. coli (ETEC)
Number of subjects: 1053
Study 7790470 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteropathogenic E. coli (EPEC)
Number of subjects: 1053
Study 7790470 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without diarrhea)
Number of subjects: 1053
Study 7790470 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteroinvasive E. coli
Number of subjects: 1053
Study 7790470 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteroaggregative and diffuse adherent E. coli
Number of subjects: 1053
Study 2216994 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 67
Study 2216994 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 67
Study 25663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg alone
Number of subjects: 150
Study 25663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg alone
Number of subjects: 150
Study 25663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg + Atropine 0.4 mg + Hyoscine 0.4 mg
Number of subjects: 150
Study 25663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg + Atropine 0.4 mg + Hyoscine 0.4 mg
Number of subjects: 150
Study 25663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam + Hyoscine
Number of subjects: 150
Study 31003212 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-aSAH syndrome group (33% of patients)
Number of subjects: 128
Study 31003212 — intervention group
Group type: COMPARATOR
Intervention: Recovery group
Number of subjects: 128
Study 31003212 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-aSAH syndrome group
Number of subjects: 128
Study 30106348 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour metformin discontinuation
Number of subjects: 90
Study 30106348 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour metformin discontinuation
Number of subjects: 90
Study 30106348 — intervention group
Group type: COMPARATOR
Intervention: No metformin discontinuation (control)
Number of subjects: 90
Study 26577455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mm MAL cream
Number of subjects: 16
Study 26577455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mm MAL cream
Number of subjects: 16
Study 26577455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mm MAL cream
Number of subjects: 16
Study 26577455 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mm MAL cream
Number of subjects: 16
Study 26577455 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-impermeable occlusion
Number of subjects: 16
Study 25506933 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-type healthy diet rich in unsaturated fat (Unsat Fat) for 6 weeks
Number of subjects: 155
Study 25506933 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-type healthy diet rich in carbohydrates (Carb) for 6 weeks
Number of subjects: 155
Study 25506933 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-type healthy diet rich in protein (Prot) for 6 weeks
Number of subjects: 155
Study 22397710 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band exercise (supervised, 2-3 times a week for 8 weeks)
Number of subjects: 41
Study 22397710 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional modality treatments only)
Number of subjects: 41
Study 20673678 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP-guided therapy
Number of subjects: 60
Study 20673678 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 60
Study 17062658 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing heliox (35% O2/65% He)
Number of subjects: 8
Study 17062658 — intervention group
Group type: COMPARATOR
Intervention: Breathing nitrox (35% O2/65% N2)
Number of subjects: 8
Study 15668637 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment
Number of subjects: 12
Study 12370681 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion, BIS-titrated
Number of subjects: 40
Study 12370681 — intervention group
Group type: COMPARATOR
Intervention: Control group (sevoflurane concentration varied based on BIS value)
Number of subjects: 40
Study 10076134 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal massage
Number of subjects: 1527
Study 10076134 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1527
Study 7478084 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH Analogues therapy
Number of subjects: 0
Study 7478084 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH Analogues therapy with Ipriflavone
Number of subjects: 0
Study 2322634 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat (HF) breakfast
Number of subjects: 15
Study 2322634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat (LF) breakfast
Number of subjects: 15
Study 2322634 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 15
Study 6112998 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallamine 10 mg
Number of subjects: 299
Study 6112998 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallamine 20 mg
Number of subjects: 299
Study 6112998 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine 5 mg
Number of subjects: 299
Study 6112998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 1 mg
Number of subjects: 299
Study 6112998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium
Number of subjects: 299
Study 31999335 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotic prophylaxis (SAP) for 2 to 14 days after admission
Number of subjects: 31
Study 31999335 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotic prophylaxis (SAP)
Number of subjects: 31
Study 31786720 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on ≥ 4 drugs
Number of subjects: 188
Study 31786720 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at risk of serious or very serious drug interactions
Number of subjects: 188
Study 31786720 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between number of drugs taken and risk of serious or very serious interaction
Number of subjects: 188
Study 27258567 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel triple IHC antibody cocktail (TNP) composed of TTF1, Napsin A, and p40.
Number of subjects: 32
Study 27258567 — intervention group
Group type: COMPARATOR
Intervention: Traditional IHC with p63, CK5/6, and TTF1.
Number of subjects: 32
Study 27699179 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtable™ medication-planning tool
Number of subjects: 674
Study 27699179 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 674
Study 25027101 — intervention group
Group type: EXPERIMENTAL
Intervention: OMEGA‐3 polyunsaturated fatty acids (200 mg/kg/day starting before anesthesia induction for 24 hours followed by 100 mg/kg/day for 7 days)
Number of subjects: 39
Study 25027101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 21733214 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 18, 36 or 72 mg/day
Number of subjects: 370
Study 21733214 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 370
Study 20863322 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 38546
Study 18936475 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon alfa (IFN)
Number of subjects: 732
Study 18936475 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa (IFN) monotherapy
Number of subjects: 732
Study 15753739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 79
Study 15753739 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 79
Study 14518526 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ)
Number of subjects: 11
Study 10758259 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific behavioral instruments (Cohen‐Mansfield agitation inventory, CERAD behavioral rating scale, revised memory and behavioral problems checklist, agitated behavior in dementia scale)
Number of subjects: 0
Study 10758259 — intervention group
Group type: COMPARATOR
Intervention: Clinical global impression of change (CGIC)
Number of subjects: 0
Study 8644655 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 bolus and infusion
Number of subjects: 2099
Study 8644655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099
Study 1354489 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing masks during surgery
Number of subjects: 14
Study 1354489 — intervention group
Group type: COMPARATOR
Intervention: Not wearing masks during surgery
Number of subjects: 14
Study 6391391 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution without bicarbonate
Number of subjects: 98
Study 6391391 — intervention group
Group type: COMPARATOR
Intervention: World Health Organisation oral rehydration solution (control)
Number of subjects: 98
Study 31375609 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigated laboratory markers
Number of subjects: 0
Study 29112461 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D supplementation (1250 mg calcium carbonate and 400 IU vitamin D3)
Number of subjects: 47
Study 29112461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 28290847 — intervention group
Group type: EXPERIMENTAL
Intervention: Akorta
Number of subjects: 60
Study 28290847 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestor
Number of subjects: 60
Study 28290847 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestor-Akorta
Number of subjects: 60
Study 28290847 — intervention group
Group type: COMPARATOR
Intervention: Akorta-Crestor
Number of subjects: 60
Study 25291126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacilli supplementation (L. rhamnosus LR06, L. pentosus LPS01, L. plantarum LP01, L. delbrueckii subsp. delbrueckii LDD01) for 15 days
Number of subjects: 29
Study 25291126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lactobacilli supplementation)
Number of subjects: 29
Study 21823209 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks intensive memory training
Number of subjects: 41
Study 21823209 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 21058198 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral formula with nutrients arginine, RNA, and ω‐3 fatty acids (Group 2)
Number of subjects: 40
Study 21058198 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formula (Group 1)
Number of subjects: 40
Study 21058198 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched enteral formula (Group 2)
Number of subjects: 40
Study 17675713 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss frame intervention
Number of subjects: 144
Study 17675713 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment frame intervention
Number of subjects: 144
Study 17675713 — intervention group
Group type: COMPARATOR
Intervention: Gain frame intervention
Number of subjects: 144
Study 15660667 — intervention group
Group type: COMPARATOR
Intervention: RGS4 SNPs (1, 4, 7, and 18) in SCZ samples
Number of subjects: 271
Study 15660667 — intervention group
Group type: COMPARATOR
Intervention: RGS4 SNPs (1, 4, 7, and 18) in BD samples
Number of subjects: 271
Study 11898769 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet with semi-solid meals (2.5 g guar gum)
Number of subjects: 15
Study 11898769 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet with semi-solid meals (without guar gum)
Number of subjects: 15
Study 11898769 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet with solid meals
Number of subjects: 15
Study 11898769 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous meal initiation
Number of subjects: 15
Study 9448176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (125 mg)
Number of subjects: 255
Study 9448176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 255
Study 7821106 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg isosorbide dinitrate
Number of subjects: 38
Study 7821106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2697886 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with ispaghula husk and propantheline (Group B)
Number of subjects: 28
Study 2697886 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 28
Study 2697886 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment after relapse on placebo
Number of subjects: 28
Study 2697886 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of active treatment
Number of subjects: 28
Study 2697886 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinstitution of active treatment
Number of subjects: 28
Study 973598 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinfandel wine (9.3% w/v alcohol)
Number of subjects: 6
Study 973598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure ethanol (9.3% w/v aqueous alcohol solution)
Number of subjects: 6
Study 973598 — intervention group
Group type: COMPARATOR
Intervention: Dealcoholized Zinfandel wine
Number of subjects: 6
Study 973598 — intervention group
Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 6
Study 31039320 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk (0.1% milk fat)
Number of subjects: 60
Study 31039320 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk (3.25% milk fat)
Number of subjects: 60
Study 31039320 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain Greek yogurt (2% milk fat)
Number of subjects: 60
Study 31039320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheddar cheese (31% milk fat)
Number of subjects: 60
Study 31039320 — intervention group
Group type: COMPARATOR
Intervention: Water (energy-free control)
Number of subjects: 60
Study 28611230 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based health coaching (10 telephone calls over 3 months)
Number of subjects: 50
Study 25671766 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1161
Study 25671766 — intervention group
Group type: COMPARATOR
Intervention: High C‐Alb levels
Number of subjects: 1161
Study 25671766 — intervention group
Group type: COMPARATOR
Intervention: C‐Alb
Number of subjects: 1161
Study 24117692 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (omeprazole and amoxicillin for 5 days followed by omeprazole, clarithromycin and metronidazole for 5 days)
Number of subjects: 360
Study 24117692 — intervention group
Group type: COMPARATOR
Intervention: 7-day standard triple therapy (omeprazole, amoxicillin and clarithromycin)
Number of subjects: 360